10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.

      Journal of Cataract and Refractive Surgery
      Aged, Aged, 80 and over, Anterior Chamber, drug effects, Anti-Infective Agents, adverse effects, therapeutic use, Antibiotic Prophylaxis, Aza Compounds, Cell Count, Endophthalmitis, microbiology, prevention & control, Endothelium, Corneal, pathology, Eye Infections, Female, Fluoroquinolones, Humans, Lens Implantation, Intraocular, Male, Middle Aged, Ophthalmic Solutions, Phacoemulsification, Quinolines, Visual Acuity

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To determine the safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution (Vigamox) in patients having cataract surgery. American Eye Center, Manila, Philippines. Preoperative and 1-month postoperative anterior chamber reaction, corneal endothelial cell density, and corneal thickness were assessed in 65 eyes that had cataract surgery with intracameral moxifloxacin. All eyes received 0.1 mL intracameral moxifloxacin 0.5% ophthalmic solution containing 500 mug of moxifloxacin as the last step of phacoemulsification. Different ophthalmologists conducted the postoperative evaluation in an observer-masked fashion. A P value less than 0.05 was considered significant. All 65 eyes completed the study. The mean age was 69.5 years +/- 9.13 (SD) (range 48 to 84 years). All eyes had a postoperative best corrected visual acuity of 20/30 or better. All eyes had trace to +2 cells and flare anterior chamber reaction only on the first day after surgery. The mean endothelial cell count was 2491.52 cells/mm(2) preoperatively and 2421.58 cells/mm(2) postoperatively. The mean difference was 70 cells/mm(2), which not statistically significant (P = .737). The increase of 17.80 microm in postoperative pachymetry 1 month after surgery was not statistically significant (P>.65). Intracameral Vigamox 0.5 mg/mL appeared to be nontoxic in terms of visual rehabilitation, anterior chamber reaction, pachymetry, and corneal endothelial cell density.

          Related collections

          Author and article information

          Comments

          Comment on this article